Recent 8-K filings for VACH
Highest-materiality recent filing
Voyager Acquisition shareholders approve Veraxa Biotech deal; 99.67% of Class A shares redeemed
- Shareholders approved business combination with Veraxa Biotech AG at March 12, 2026 meeting.
- 25,217,315 Class A shares redeemed (~99.67%), leaving ~$885,556 in trust account.
-
Voyager/Veraxa secure $27.5M senior secured notes and $50M share purchase agreement
$27.5M senior secured notes due Aug 2027, monthly amortization of $2.75M, with warrants to buy 2.39M shares at $11.50.
-
Voyager Acquisition shareholders approve Veraxa Biotech deal; 99.67% of Class A shares redeemed
Shareholders approved business combination with Veraxa Biotech AG at March 12, 2026 meeting.
-
VERAXA shareholders approve merger with Voyager SPAC; CHF 223,400 capital increase
Shareholders approved absorption merger of VERAXA into Veraxa Biotech Holding AG; combined entity to rename to Veraxa Biotech AG.
-
Voyager Acquisition raises Veraxa merger consideration to $1.35B; sponsor to forfeit shares
Aggregate merger consideration increased by $50M to $1,350,000,000.
-
SPAC Voyager to combine with Veraxa Biotech at ~$1.5B enterprise value; close expected Q4 2025
Pro forma combined enterprise value of ~$1.5B; Veraxa shareholders roll over 100% of equity.
-
Voyager Acquisition Corp. to merge with Veraxa Biotech AG; expected Q4 2025 close
SPAC will merge with Merger Sub, then Veraxa will merge into PubCo, a Swiss public company.
-
Voyager Acquisition Corp. closes $253M IPO and $7.7M private placement
Closed IPO of 25,300,000 units at $10.00 each, generating $253.0M in gross proceeds.
Materiality & sentiment trend
Max materiality 0.85 · Median 0.65 · Most common event m_and_a